

PRACTICE OF L-ASPARAGINASE USAGE: A SURVEY AMONG HEALTHCARE PROVIDERS TREATING CHILDREN WITH CANCER IN INDIA

Archana MV¹, Kalasekhar Vijayasekharan², Vinay Munikoty¹, Ramitha Bhat R¹, Atul Achyutrao¹, Vani Lakshmi R¹, and Vasudeva K¹

¹Manipal Academy of Higher Education

²Regional Cancer Centre Thiruvananthapuram

July 8, 2022

Abstract

Introduction: L-Asparaginase is an essential chemotherapeutic agent in the therapy of Acute Lymphoblastic Leukemia (ALL), which has led to improvement in survival. In low and middle-income countries like India, the outcomes in ALL are inferior compared to the published literature, one of the cause of which are believed to be due to the inferior quality of bioequivalent Asparaginase. The following survey attempts to understand the practice of using this agent among oncologists treating children with cancer in our country. **Methods:** The researchers designed a structured online questionnaire comprising 25 aspects of L-Asparaginase usage in the study. The questionnaire was directed to the healthcare providers involved in treating children with cancer in India. **Results:** Of the total 80 responses recorded, 51 (64%) respondents had more than five years of experience in pediatric oncology and were treating at least 5-10 newly diagnosed ALL patients per month. Forty-one (51%) respondents utilized Native Asparaginase, and 21 (26.3%) oncologists used PEGylated-Asparaginase exclusively. The most common route of administration was the intramuscular route (66.3%). Seventy percent of respondents utilized Native form at a dose of 10,000IU/m² and 20% at 6000IU/m². The amounts used for PEGylated L-Asparaginase were 1000IU/m², 2500IU/m², and variable doses in 48%, 40%, and 10% of responses, respectively. Though Serum Asparaginase assay (SAA) was not measured routinely in most of the centres, 39 (48.8%) healthcare providers perceived performing SAA helps to make the clinical decision. **Conclusion:** This survey shows a wide variation in L-Asparaginase usage among healthcare providers caring for children with cancer in our country. As L-Asparaginase is the pivotal component of ALL therapy, uniformity in its usage and dosing with the possibility of monitoring SAA due to the quality of bioequivalent may be one of the critical steps towards improving outcomes in ALL in our country.

1 INTRODUCTION

Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children as it represents approximately 25% of cancer diagnoses among children below 15 years. Management of ALL has evolved over many decades; with a risk-based approach, treatment intensification, and better supportive care, survival rates in children have progressively risen to nearly 90%.¹ L-Asparaginase is an integral component of treatment for children with ALL and since its introduction by the Dana Farber group in 1977 into pediatric treatment protocols survival has significantly improved.^{2,3}

There are three currently available L-Asparaginase preparations approved for clinical applications: *Escherichia coli* derived native *E.coli* Asparaginase, PEGylated Asparaginase (PEG Asparaginase), and *Erwinia chrysanthemi* derived *Erwinia* Asparaginase. All presently available Asparaginase preparations share the same mechanism of action – the deamination and depletion of asparagine, an essential amino acid for the lymphoblast. Yet, each displays a markedly different pharmacokinetic profile.^{4,5} PEG Asparaginase has a

significantly longer half-life and is less immunogenic than the native Asparaginase.⁶ When used in front-line therapy to replace native Asparaginase as part of combination chemotherapy, PEG Asparaginase has shown comparable efficacy.⁷

In clinical practice, the enzyme is currently given by the intravenous, intramuscular or subcutaneous route, with dosages being different across various protocols followed.⁸ Asparaginase activity of 100 IU/L at desired time point for the molecule is considered to be sufficient for complete asparagine depletion.⁹ Although this might theoretically result in different pharmacokinetic profiles, information on the comparability of the routes of administration is limited about the currently available preparations.

Therapeutic drug monitoring of Serum Asparaginase Activity (SAA) level helps individualise Asparaginase dosing. The common side effects encountered with Asparaginase are hypersensitivity reactions, silent inactivation, cerebral sinus venous thrombosis, pancreatitis, hyperglycemia, hypertriglyceridemia, and liver dysfunction (hyperbilirubinemia and transaminitis). There is heterogeneity among healthcare providers in the usage of L-Asparaginase concerning preparations used, doses and route of administration, therapeutic drug monitoring, and toxicity profile observed along with dilemma of choosing a bioequivalent drug. The present survey attempts to understand the Asparaginase usage practice among healthcare providers in India, which will pave the way for effective designing of future clinical trials associated with pediatric oncology.

2 METHODOLOGY

A descriptive cross-sectional survey design was employed to assess the L-Asparaginase usage practice among healthcare providers treating children with cancer in India. The survey was conducted through the smart survey platform. Firstly, the researchers sent an email invite to all the potential participants associated with the study. The researchers sent fortnightly reminders to the participants during the data collection process to minimise the non-responses. Data collected through this platform was digitally stored in a designated device as an encrypted file. The data was transferred and securely stored in a hard drive upon completing the data collection process.

The researchers have designed a three-part survey containing 25 questions to collect data from study participants. The first part consisted of information about the survey and consent. The second part included five questions to capture the demographic details of the survey participant, and the last part had 20 questions aimed to assess the Asparaginase usage practices of the respondents. Out of the 20 core questions, 14 were multiple choice questions, and the remaining six were dichotomous questions. A pilot survey on five pediatric oncologists was implemented to check content validity and comprehensibility, of the questionnaire, the results of which was excluded from the present data analysis.

The participant's responses to the survey questionnaire were recorded on Microsoft Excel 2016 and quantitatively analysed using IBM SPSS 16.0. Descriptive statistics were implemented in the present study. The Institutional Ethics Committee (IEC), Kasturba Hospital and Kasturba Medical College, Manipal (IEC 532/2020) approved the study protocol.

3 RESULTS

The researchers received responses from 80 healthcare providers treating children with cancer across India. The demographics of the healthcare providers participating in the survey is presented in Table 1.

3.1 Type and dose of Asparaginase

The most common Asparaginase used by Indian pediatric oncologists is native E coli Asparaginase. Forty-one (51.2%) respondents used the native form exclusively, whereas 21 (26.3%) respondents used PEGylated Asparaginase exclusively and 18 (22.5%) respondents used both forms (Figure 1). Erwinia Asparaginase is unavailable in India and was not used. There was no statistically significant relationship between the practice setting and the type of Asparaginase used by the healthcare providers ($p=0.489$). There was significantly more utilisation of PEG Asparaginase among participants who had 5-10 years of experience ($p=0.04$). Fifty-six (70%) respondents used 10,000U/m²/dose of native Asparaginase. Sixteen (20%) and 8 (10%) respondents

used native Asparaginase at 6,000U/m²/dose and variable dose, respectively. Most of the participants (78%, n=62) used a 72-hour dosing interval while administering native Asparaginase. In the case of PEGylated Asparaginase 39 (48.8%), 32 (40%) and 9 (11.3%) respondents utilised 1000U/m²/dose, 2500U/m²/dose and variable dose regimen respectively. When asked about the preferred route of administration of Asparaginase, 66% (n=53) used the intra-muscular (IM) route and 29% (n=23) respondents gave the drug by intra-venous (IV) route, details of which is depicted in Figure 2.

3.2 Side effect profile

In order to understand the side effect profile of Asparaginase, participants were asked multiple-choice questions with options consisting of various side effects of Asparaginase such as hypersensitivity reaction, liver dysfunction (hyperbilirubinemia and transaminitis), hyperglycemia needing medication, cerebral sinus venous thrombosis, and pancreatitis. Further to this question elaborated the phase in which side effects were observed (Induction vs re-induction/delayed intensification), and the type of Asparaginase utilised. The most common side effect observed by survey participants is hypersensitivity reaction followed by liver dysfunction. Frequency of hypersensitivity reaction was more in re-induction (40% in induction vs. 72% in re-induction with respect to native Asparaginase). As per the respondents, the frequency of hypersensitive reactions were lesser with the utility of PEG Asparaginase as compared to native formulation, which was statistically significant (p=0.01). The side effect profile, route of administration and the dose of Asparaginase (native or PEGylated) lacked correlation with adverse events. The side effect profile is presented in Figures 3.

3.3 Facts and perception about Asparaginase usage

Though the most common side effect observed was hypersensitivity reaction, 58% (n=47) of responders were willing to re-challenge L-Asparaginase. In 67% of instances, participants opted to re challenge with PEG Asparaginase, and 16% with native E coli Asparaginase. Forty-four responders (55%) re challenged the drug under premedication. When participants were asked whether they are willing to re-challenge patients who developed pancreatitis to native L-Asparaginase in the past, during re-induction/delayed intensification, 61 responders (76.3%) were against re challenging Vs. 19 who are willing to re-challenge.

Though more than 50% of participants are utilising the drug within 24 hours of opening the vial, nearly 45% of responders are storing the leftover drug for future use. Most (n=75, 94%) clinicians neither measured serum fibrinogen level routinely nor did they give fresh frozen plasma transfusion for replacing plasma factor.

Participants were given a dichotomous question stating do you monitor serum Asparaginase activity (SAA) level in your practice, about 73 responders (91 %) did not do it routinely, whereas about 9% of participants were doing it in their practice. Further to this when participants were asked whether monitoring SAA level help in their clinical decision, 46% perceived it will benefit whereas 48% were not sure about the clinical benefit of the same.

4 DISCUSSION

This survey investigated Asparaginase usage practice among healthcare providers treating children with cancer in India. Despite Asparaginase being a prime catalyst in improving the outcome of pediatric ALL, there is a wide variation in its usage practice in India. PEGylated Asparaginase has replaced native Asparaginase for treatment of pediatric ALL because of its prolonged effect, lower incidence of silent antibodies, similar safety profile, and convenience.⁶ Many international pediatric ALL trials have shown promising outcomes with PEGylated Asparaginase.^{10,11} Despite this in India, most survey participants use native formulation probably due to the higher cost and non-availability of PEGylated formulation under certain national health schemes. As per this study, respondents majorly utilised the IM route, perhaps because this method is less time-consuming, does not require a test dose to be given and has ease of administration especially in high-volume centers. There was no statistically significant difference in reporting of mean hypersensitivity reaction rate between the IM and IV route, which is in accordance with the randomised study by the Dana Farber group.¹²

Incidence of hypersensitivity reaction varies depending on formulation, route, and frequency of administra-

tion. These hypersensitivity reactions are mediated by neutralising antibodies in most instances. However, with the use of intravenous PEGylated Asparaginase, a distinct type of acute clinical reaction (a non-allergic infusion reaction) is becoming increasingly recognised, and it is nearly impossible to distinguish this reaction from allergic hypersensitivity clinically. In this survey, hypersensitivity reaction was the most common adverse event noticed by participants, even for PEGylated Asparaginase during induction chemotherapy. As per a well-known study, a policy of universal premedication to prevent infusion-related reaction with therapeutic drug monitoring might significantly benefit our patient.¹³

As per the study findings, more than 90% of participants did not carry out therapeutic drug monitoring, but nearly 50% of participants felt that it would benefit their clinical decision. A study highlights the importance of therapeutic drug monitoring in individualised PEGylated Asparaginase dose.¹⁴ However, in the present study, participants opted to pre-medicate while re-challenging Asparaginase without monitoring drug level, which might mask allergic reaction resulting in sub therapeutic levels hampering desired outcomes. As per the experiences from two oncology centre in India, there was a concern regarding unsatisfactory quality and therapeutic activity of biogeneric native Asparaginase marketed in India.^{15,16} A prospective observational study from North India demonstrated that achievement of adequate SAA level with generic brands of PEGylated Asparaginase. This could be the way forward for LMIC to utilise economical generic brands along with therapeutic drug monitoring.¹⁷

The side effect profile seen in India is almost similar to the side effect seen worldwide.¹⁸ Apart from an allergic reaction, another common reason for discontinuing Asparaginase therapy is pancreatitis; nearly 75% of survey participants were not re-exposing the drug following an episode of Asparaginase-associated pancreatitis. There is a significant negative impact of discontinuing Asparaginase, especially in high-risk patients.¹⁹ Hence, the decision to discontinue should be taken with caution, considering the severity of the initial episode and additional risk factors for pancreatitis.²⁰ There is a need for prospective studies to define “re-challenge strategy” following Asparaginase-associated pancreatitis.

The present survey utilized an online method to obtain information from participants across the country. There were instances of multiple participants from the same institute/hospital vis-a-vis, no representation from a few institutions. Although the data from the survey can be utilised for identifying research gaps and proposing research questions, the survey results cannot be extrapolated for clinical use.

In conclusion, this survey shows a wide variation in L-Asparaginase usage among healthcare providers caring for children with cancer in our country concerning the formulation, dose and route of administration. As L-Asparaginase is the pivotal component of ALL therapy, uniformity in its usage and dosing is the need of the hour. With the availability of multiple generic brands, therapeutic drug monitoring of SAA should be a critical step towards improving outcomes in ALL in our country. We need prospective nationwide studies to define optimal asparagine depletion and the level of enzyme activity required in our population.

ACKNOWLEDGEMENTS

The authors thank the five subject experts who participated in the pilot study and all the pediatric haematologists and oncologists who participated in the survey.

REFERENCE

1. Bernard J, Weil M, Jacquillat C. Treatment of acute lymphoblastic leukemia. *N Engl J Med* . 2006;354(2):1-11. doi:10.1056/NEJMRA052603
2. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG. Influence of Intensive Asparaginase in the Treatment of Childhood Non-T-Cell Acute Lymphoblastic Leukemia. *Cancer Res* . 1983;43(11).
3. Clavell LA, Gelber RD, Cohen HJ, et al. Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic Leukemia. *N Engl J Med* . 1986;315(11):657-663. doi:10.1056/nejm198609113151101

4. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. *J Clin Oncol* . 1993;11(9):1780-1786. doi:10.1200/JCO.1993.11.9.1780
5. Lanvers-Kaminsky C. Asparaginase pharmacology: challenges still to be faced. *Cancer Chemother Pharmacol* 2017 793 . 2017;79(3):439-450. doi:10.1007/S00280-016-3236-Y
6. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native *Escherichia coli* asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. *Blood* . 2002;99(6):1986-1994. doi:10.1182/blood.V99.6.1986
7. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. *Blood* . 2010;115(7):1351-1353. doi:10.1182/BLOOD-2009-09-245951
8. Rizzari C, Asselin B. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. *Leuk Lymphoma* . 2015;56(8):2273-2280. doi:10.3109/10428194.2014.1003056
9. Brigitha LJ, Pieters R, van der Sluis IM. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review. *Eur J Cancer* . 2021;157:238-249. doi:10.1016/J.EJCA.2021.08.025
10. Vora A, Wade R, Mitchell C, Goulden N, Richards S. Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003. *Blood* . 2008;112(11):909-909. doi:10.1182/BLOOD.V112.11.909.909
11. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA Drug Approval Summary: Pegaspargase (Oncaspar) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). doi:10.1634/theoncologist.12-8-991
12. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native *Escherichia coli* l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. *Lancet Oncol* . 2015;16(16):1677-1690. doi:10.1016/S1470-2045(15)00363-0
13. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. *Pediatr Blood Cancer* . 2019;66(8):e27797. doi:10.1002/PBC.27797
14. Kloos RQH, Pieters R, Jumelet FMV, De Groot-Kruseman HA, Van Den Bos C, Van Der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. *J Clin Oncol* . 2020;38(7):715-724. doi:10.1200/JCO.19.02292
15. Sankaran H, Sengupta S, Purohit V, et al. A comparison of asparaginase activity in generic formulations of *E.coli* derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia. *Br J Clin Pharmacol* . 2020;86(6):1081-1088. doi:10.1111/bcp.14216
16. Sidhu J, Gogoi MP, Agarwal P, et al. Unsatisfactory quality of *E. coli* asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. *Pediatr Blood Cancer* . 2021;68(11). doi:10.1002/PBC.29046
17. Vyas C, Jain S, Kapoor G, Mehta A, Takkar Chugh P. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity. *Pediatr Hematol Oncol* . 2018;35(5-6):331-340. doi:10.1080/08880018.2018.1538277
18. Hijiya N, Van Der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. *Leuk Lymphoma* . 2016;57(4):748-757. doi:10.3109/10428194.2015.1101098

19. Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the children's oncology group. *J Clin Oncol* . 2020;38(17):1897-1905. doi:10.1200/JCO.19.03024


20. Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. *Paediatr Drugs* . 2021;23(5):457-463. doi:10.1007/S40272-021-00463-1


Figure description

Figure 1: Frequency of utilization of different types of Asparaginase

Figure 2: Preferred route of administration of Asparaginase

Figure 3: Side effects profile of Asparaginase as observed by Pediatric Hematologists and Oncologists in India. (A) Side effect frequency of native E.coli Asparaginase during Induction. (B) Side effect frequency of native E.coli Asparaginase during Re-induction/ Delayed intensification. (C) Side effect frequency of PEGylated Asparaginase during Induction. (D) Side effect frequency of PEGylated Asparaginase Re-induction/ Delayed intensification.





Hosted file

Table 1.docx available at <https://authorea.com/users/493899/articles/576180-practice-of-l-asparaginase-usage-a-survey-among-healthcare-providers-treating-children-with-cancer-in-india>